King Pharmaceuticals, Inc. (NYSE:KG) today held a conference call at 10:00 AM ET to discuss its proposal to acquire Alpharma Inc. (NYSE:ALO) for $33.00 per share in cash.
Playback of the conference call and the webcast will be available for replay through the close of business on August 29, 2008. The replay can be accessed by dialing 888-346-3949 or 404-260-5385 (toll/international), conference number: 20080818183818, PIN: 182778123. Accompanying slides and the conference call webcast will also be available at http://www.Kingpharm.com/web_casts.asp.
About King Pharmaceuticals, Inc.
King, headquartered in Bristol, Tennessee, is a vertically integrated branded pharmaceutical company. King, an S&P 500 Index company, seeks to capitalize on opportunities in the pharmaceutical industry through the development, including through in-licensing arrangements and acquisitions, of novel branded prescription pharmaceutical products and technologies that complement the Company’s focus in specialty-driven markets, particularly neuroscience, hospital and acute care. King strives to be a leader and partner of choice in bringing innovative, clinically-differentiated medicines and technologies to market.
Forward-looking Statements
This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the “Act”). King Pharmaceuticals, Inc. (“King”) disclaims any intent or obligation to update these forward- looking statements, and claims the protection of the Safe Harbor for forward- looking statements contained in the Act. All statements contained in this document that are not clearly historical in nature or that necessarily depend on future events are forward- looking, and the words “anticipate,” “believe,” “expect,” “estimate,” “plan,” and similar expressions are generally intended to identify forward-looking statements. Such statements are based on management’s current expectations, but actual results may differ materially due to various factors such as King’s ability to achieve the synergies and value creation contemplated by the proposed transaction; King’s ability to promptly and effectively integrate the businesses of Alpharma Inc.
No comments:
Post a Comment